.
To address the capacity of FPRs to provide longterm benefit after myocardial injury, a dual agonist of FPR1/2 identified as Compound 43 (Cmpd43) (11) (12) (13) was administered orally to evaluate relationships between heart structure and function after MI.
In addition, the signaling and cellular response stimulated by Cmpd43 and regulation of key cytokines associated with proinflammatory and proresolution phases are described.
METHODS
For an expanded Methods section, please see the Online Appendix. The signaling profile of Cmpd43 was determined in HEK293 cells that transiently expressed either FPR1 or FPR2. Activation of G proteins (Gai1, Gai2, Gai3, GaoA, GaoB, Ga12, and Ga13) and recruitment of b-arrestins (b-arrestin-1 and b-arrestin-2) were measured using bioluminescence resonance energy transferÀbased biosensor assays (14) .
Phagocytosis was evaluated using BioGel-elicited peritoneal macrophages from wild-type (WT) C57BL/6 mice and FPR1 and FPR2 knockout (KO) mice. were harvested 2 h after dosing for macrophage marker assays as described in the following section.
In the rat IR experiments, treatment groups were DATA AND STATISTICAL ANALYSIS. Statistical significance was determined using a Student's t-test or analysis of variance followed by a Dunnett's post hoc Figures 1F and 1G ), but not for Gaq, Ga11, or Gas biosensors (Online Figure 1 ). This Dunnett's versus medium: **p < 0.01, ***p < 0.001, ****p < 0.0001. Dunnett's versus SAA: †p < 0.05, † †p < 0.01, † † †p < 0.001, † † † †p < 0.0001. Other abbreviations as in Figures 1 and 2 .
Continued on the next page
García et al. Phagocytes respond to chemotactic stimuli and degrade internalized particles and bacteria while undergoing an oxidative respiratory burst (19) . The capacity of Cmpd43 to stimulate oxidative burst activity and chemotaxis was investigated using differentiated human promyelocytic leukemia HL-60 cells, which possess a neutrophil-like lineage (20) . García et al. 
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García et al. Figure 5B shows the effects of treatments on chamber dilatation. Treatment with Cmpd43 attenuated chamber expansion at the 1 and 10 mg/kg doses (À28 and À30% vs. vehicle, respectively; p < 0.05).
The chamber areas for Cmpd43-treated mice were similar in size to noninfarcted shams. Infarct wall thicknesses were measured for all groups ( Figure 5C ). Figures 1, 4 , and 5.
Abbreviations as in
García et al. were measured for all groups ( Figure 6B ). Scar strain measurements along the short axis of the heart (circumferential E 11 direction) are shown in Figure 6C .
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Sham hearts were analyzed in a region of the left ventricle where infarction was predicted to occur. For the sham group, E 11 strains were small (i.e., stiff myocardium). By contrast, vehicle showed the highest scar strains in the E 11 direction, which suggested an Figure 7C ) (p < 0.05). As shown in Figure 7D , infarcted rats treated with vehicle showed a mean ejection fraction of 38%, whereas noninfarcted sham hearts had an ejection fraction average of 67%.
Treatment with Cmpd43 yielded a statistically significant relative improvement in ejection fraction of 32% versus vehicle (12% absolute increase; p < 0.05). Table 1 summarizes the various hemodynamic parameters measured in the study. Regional measurements of viable myocardium relative to infarct scar tissue were made transmurally across the infarct wall (i.e., from epicardium to endocardium) ( Figure 7E ). Interestingly, when phagocytosis experiments were carried out with FPR1-deficient macrophages, a decrease in potency was observed, which suggested 
